ProxyMiner / Company

AbbVie Inc.ABBV

Latest proxy: 2026 · view on SEC ↗ · CIK 0001551152

CEO total pay

$32,530,984

Robert A. Michael · 2025

Say on pay

93.1%

Latest disclosed shareholder vote

CEO pay ratio

Not in CD&A

Median employee: $169,019

Compensation committee

Committee Report

Compensation Committee

Per the latest proxy

Filings indexed: 2 · 2026 · 2025

Executive pay

What did they pay them?

From the Summary Compensation Table. Pay mix and YoY are computed from these rows.

ExecutiveRoleTotalYoYPay mixSalaryStockCash incentiveOther
Robert A. Michael2025 compensation
Chairman of the Board and Chief Executive Officer
$32,530,984 76%
88% at-risk
$1,700,000$13,268,456$516,293
Scott T. Reents2025 compensation
Executive Vice President, Chief Financial Officer
$12,353,002 12%
77% at-risk
$1,124,116$4,353,512$472,797
Jeffrey R. Stewart2025 compensation
Executive Vice President, Chief Commercial Officer
$15,435,304 10%
77% at-risk
$1,315,726$5,390,310$737,376
Azita Saleki-Gerhardt2025 compensation
Executive Vice President, Chief Operations Officer
$10,791,976 9%
73% at-risk
$1,052,581$3,980,457$820,310
Roopal B. Thakkar2025 compensation
Named executive officer
$9,912,843
80% at-risk
$1,146,154$3,980,457$59,767

Pay mix: base cash incentive equity other

CD&A excerpt

Compensation discussion & analysis

Opening passage of the loaded filing's CD&A. Use Ask below to query the full text with citations.

This Compensation Discussion and Analysis (CD&A) describes the pay philosophy established for AbbVie's named executive officers (NEOs), the design of our compensation programs, the process used to examine performance in the context of executive pay decisions, and the performance goals and results for each NEO: ROBERT A. MICHAELChairman of the Board and Chief Executive OfficerSCOTT T. REENTS Executive Vice President, Chief Financial OfficerJEFFREY R. STEWARTExecutive Vice President, Chief Commercial OfficerAZITA SALEKI-GERHARDTExecutive Vice President, Chief Operations OfficerROOPAL B. THAKKARExecutive Vice President, Research & Development and Chief Scientific Officer Although we describe our programs in the context of the NEOs, it is important to note that our programs generally have broad eligibility and therefore in most cases apply to employee populations outside the NEO group as well. The content of this section is organized according to the following. ​​​EXECUTIVE SUMMARY32 ​ ​ ​COMPENSATION PLAN ELEMENTS39Compensation Philosophy32​Base Salary39Business Performance Highlights33​Short-Term Incentives and 2025 Results39Stockholder Engagement35​Long-Term Incentives and 2025 Resu

Read the full CD&A on SEC.gov ↗

Peer comparison

Who they benchmark against

Click any peer to jump to their proxy. Peers we haven't ingested yet kick off an import on click.

Governance

Policy guardrails

  • stock ownership guidelines

    present

    STOCK OWNERSHIP GUIDELINES

  • change in control

    CHANGE IN CONTROL AGREEMENTS

    CHANGE IN CONTROL AGREEMENTS

  • compensation consultant

    independent

    independent compensation consultant

  • compensation committee

    Compensation Committee

    Compensation Committee

  • hedging

    ANTI-HEDGING AND ANTI-PLEDGING POLICIES

    ANTI-HEDGING AND ANTI-PLEDGING POLICIES

  • pledging

    prohibited

    AbbVie also has a formal policy that prohibits directors and officers subject to Section 16 of the Exchange Act, including the NEOs, from pledging AbbVie common stock as collateral for a loan.

  • clawback

    present

    CLAWBACK POLICY

Performance markers

Metric facts

  • revenue

    $47.3

    A formal payout matrix based on Platform Revenue and Non-GAAP Income Before Taxes guides the committee by capping the range of final awards at or below the plan maximum of 200% of target. The matrix is used to ensure ali

  • say on pay

    93.1%

    At our 2025 Annual Meeting, the say on pay proposal received support from 93.1% of our stockholders.

  • median employee compensation

    $169,019

    REQUIRED PAY RATIO DISCLOSURE As required by Section 953(b) of the Dodd-Frank Wall Street Reform and Consumer Protection Act and Item 402(u) of Regulation S-K, we are providing the following information about the relatio

Ask

Anything about AbbVie Inc.’s 2026 proxy

Answers are grounded in the loaded filing and cite specific artifacts. Bring your own free Google AI Studio key.

Loading the Ask interface…